Results 11 to 20 of about 20,809 (211)

Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss

open access: yesMedComm
Somatic retinoblastoma 1 (RB1) loss is prevalent across different cancer types and is enriched in treatment‐refractory tumors, such as castration‐resistant prostate cancer (CRPC) and small‐cell lung cancer, but cannot be considered as a direct druggable ...
Tao Zhou   +21 more
doaj   +2 more sources

Preparation and characterization of 6-mercaptopurine-coated magnetite nanoparticles as a drug delivery system [PDF]

open access: yesDrug Design, Development and Therapy, 2013
Dena Dorniani,1 Mohd Zobir bin Hussein,1 Aminu Umar Kura,2 Sharida Fakurazi,2 Abdul Halim Shaari,3 Zalinah Ahmad4 1Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology, 2Vaccines and Immunotherapeutics Laboratory ...
Dorniani D   +5 more
doaj   +2 more sources

Design and development of hydrogel nanoparticles for mercaptopurine

open access: yesJournal of Advanced Pharmaceutical Technology & Research, 2010
Hydrogel nanoparticles have gained attention in recent years as they demonstrate the features and characters of hydrogels and nanoparticles at the same time.
V Senthil   +5 more
doaj   +2 more sources

Clinical pharmacists’ knowledge, attitude, perception, and beliefs about the role of pharmacogenetic testing for genes polymorphisms when prescribing mercaptopurine

open access: yesSaudi Pharmaceutical Journal
Background: Single nucleotide polymorphisms in the gene encoding proteins involved in mercaptopurine metabolism can influence drug efficacy and safety. This study aims to assess clinical pharmacists’ knowledge about mercaptopurine-related genes and their
Norah O. Abanmy   +3 more
doaj   +2 more sources

Genetic risk variants in intestinal inflammatory disorders [PDF]

open access: yes, 2010
PhDThis thesis includes work on the genetics of intestinal inflammatory disorders, concentrating on coeliac disease and Crohn’s disease. It explores how common genetic variants influence risk of complex phenotypes including immunological intolerance to
Dubois, Patrick Charles Alexander
core   +3 more sources

Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease [PDF]

open access: yes, 2008
AIM:To investigate the efficacy of 6-mercaptopurine (6-MP) in cases of azathioprine (AZA) hypersensitivity in patients with inflammatory bowel disease. METHODS: Twenty nine previously confirmed Crohn’s disease (CD) (n = 14) and ulcerative colitis (UC)
Nagy, Ferenc   +5 more
core   +1 more source

Polyglycolic Acid Shield Prevents Repeated Delayed Bleeding After Endoscopic Stricturotomy for Anastomotic Stricture in Crohn's Disease: A Case Report. [PDF]

open access: yesDEN Open
ABSTRACT Endoscopic stricturotomy (ES) is a novel approach for treating benign strictures of the lower gastrointestinal tract. However, it is performed at a limited number of facilities, and strategies for preventing complications have not yet been established. We performed ES for ileo‐sigmoid anastomosis associated with Crohn's disease (CD).
Kikuchi H   +9 more
europepmc   +2 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Theoretical EPR study of 6-Mercaptopurine [PDF]

open access: yes, 2017
32nd International Physics Congress of Turkish-Physical-Society (TPS) -- SEP 06-09, 2016 -- Bodrum, TURKEY6-Mercaptopurine is important antineoplastics agent and it is used for immuno suppressive and anti inflammatory.
Ercan Türkkan   +3 more
core   +1 more source

Experts opinion on the practical use of azathioprine and 6-mercaptopurine in inflammatory bowel disease [PDF]

open access: yes, 2016
The relevance of azathioprine and 6-mercaptopurine therapy in inflammatory bowel disease, Crohn's disease, and ulcerative colitis, has been challenged in recent publications.
Kessler-Brondolo, Vera   +29 more
core   +2 more sources

Home - About - Disclaimer - Privacy